Articles related to CLINICAL TRIALS

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.

Pemgarda™ emerges as a pivotal development in COVID-19 prophylaxis, particularly for patients with moderate to severe immune compromise, providing a new layer of defense for those less responsive to vaccination.

In the latest findings on gantenerumab, while the anticipated cognitive benefits in Alzheimer’s patients were not realized, the drug demonstrated significant impacts on biomarkers, including amyloid plaque reduction and alterations in CSF phosphorylated tau and Aβ42 levels.

A 2019 trial report from NEJM offered a comparative analysis of levetiracetam, fosphenytoin, and valproate in managing benzodiazepine-resistant convulsive status epilepticus, providing essential insights into their efficacy and safety, aiding clinicians in informed decision-making.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.